CA2593956A1 - Agents inhibiting the cathelin-like protein cap18/ll-37 - Google Patents

Agents inhibiting the cathelin-like protein cap18/ll-37 Download PDF

Info

Publication number
CA2593956A1
CA2593956A1 CA002593956A CA2593956A CA2593956A1 CA 2593956 A1 CA2593956 A1 CA 2593956A1 CA 002593956 A CA002593956 A CA 002593956A CA 2593956 A CA2593956 A CA 2593956A CA 2593956 A1 CA2593956 A1 CA 2593956A1
Authority
CA
Canada
Prior art keywords
cells
agent
hcap18
agent according
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002593956A
Other languages
English (en)
French (fr)
Inventor
Mona Stahle
Johan Heilborn
Margareta Frohm Nilsson
Gunter Webber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipopeptide AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2593956A1 publication Critical patent/CA2593956A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002593956A 2004-12-22 2005-12-16 Agents inhibiting the cathelin-like protein cap18/ll-37 Abandoned CA2593956A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63775904P 2004-12-22 2004-12-22
US60/637,759 2004-12-22
PCT/GB2005/004900 WO2006067402A2 (en) 2004-12-22 2005-12-16 Agents inibiting the cathelin-like protein cap18/ll-37

Publications (1)

Publication Number Publication Date
CA2593956A1 true CA2593956A1 (en) 2006-06-29

Family

ID=36283015

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002593956A Abandoned CA2593956A1 (en) 2004-12-22 2005-12-16 Agents inhibiting the cathelin-like protein cap18/ll-37

Country Status (6)

Country Link
US (1) US7741275B2 (enExample)
EP (1) EP1846444A2 (enExample)
JP (1) JP2008525005A (enExample)
CN (1) CN101142233A (enExample)
CA (1) CA2593956A1 (enExample)
WO (1) WO2006067402A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0608797D0 (en) * 2006-05-04 2006-06-14 Lipopeptide Ab Novel agents and the use thereof
WO2007148078A1 (en) * 2006-06-20 2007-12-27 Lipopeptide Ab Use cathelicidin antimicrobial protein (hcap18 ) as anticancer agent
US20120315290A1 (en) * 2006-12-15 2012-12-13 Board Of Regents, The University Of Texas System Inhibitors of ll-37 mediated immune reactivity to self nucleic acids
CN101571549B (zh) * 2008-04-30 2013-08-14 上海泽润生物科技有限公司 Vero细胞HCP检测试剂盒及其应用
DK3252068T3 (da) 2009-10-12 2025-08-25 Larry J Smith Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
CN111973805B (zh) * 2019-08-16 2022-03-01 苏州吉美瑞生医学科技有限公司 抗菌肽hCAP18/LL-37在抗感染生物工程肺中的应用
JP2023539590A (ja) * 2020-08-26 2023-09-15 シラ セラピューティック インコーポレイティッド 吸入用治療剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5149796A (en) 1989-08-31 1992-09-22 City Of Hope Chimeric DNA-RNA catalytic sequences
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
PL178438B1 (pl) 1994-02-04 2000-04-28 Scotia Lipidteknik Ab Preparat dwuwarstwy lipidowej, środek farmaceutyczny zawierający preparat dwuwarstwy lipidowej i sposób wytwarzania środka farmaceutycznego
CN1091591C (zh) 1994-02-04 2002-10-02 利珀克尔集团公司 亲脂载体制剂
JP3117145B2 (ja) 1994-02-04 2000-12-11 スコーツイア・リピツドテクニク・アクチエボラーグ 水中油エマルジョン
EP1358888A1 (en) 2002-02-28 2003-11-05 Robert Bals The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
JPWO2004009640A1 (ja) 2002-07-22 2005-11-17 生化学工業株式会社 抗菌性ペプチドに対する抗体及びその利用
AU2003288507A1 (en) * 2002-12-19 2004-07-14 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
WO2004098536A2 (en) * 2003-03-06 2004-11-18 The Regents Of The University Of California Anti-viral activity of cathelicidin peptides

Also Published As

Publication number Publication date
WO2006067402A2 (en) 2006-06-29
JP2008525005A (ja) 2008-07-17
CN101142233A (zh) 2008-03-12
WO2006067402A3 (en) 2006-09-08
EP1846444A2 (en) 2007-10-24
US7741275B2 (en) 2010-06-22
US20080187530A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
Zhang et al. Stomatin-like protein 2 is overexpressed in cancer and involved in regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma
KR102340685B1 (ko) 암의 진단 및 치료를 위한 방법 및 조성물
Qu et al. Targeting mechanosensitive MDM4 promotes lung fibrosis resolution in aged mice
WO2009030884A2 (en) Mannosylated butyrophilin tumour markers
JP2014088393A (ja) トレフォイル因子およびそれを用いた増殖性疾患の処置方法
CN107249636A (zh) 以ckap4作为靶分子的抗肿瘤剂
EP3124035B1 (en) Novel cancer antigen eef2
US20100056431A1 (en) Medical uses
US7741275B2 (en) Agents and use thereof
AU2007251359A1 (en) Inhibitors of hCAP18/LL-37 for use in the treatment of breast cancer
US20150329639A1 (en) Compositions and methods for regulating erythropoiesis
AU2007251362A1 (en) Combination therapy product and uses thereof
JP7864075B2 (ja) 抗ｉｇｓｆ１抗体及びその使用
CN113398270B (zh) 一种治疗骨巨细胞瘤的方法
Zhou et al. Context‐Dependent Role of GDF15: GDF15+ Tumor‐Associated Macrophages Suppress OSCC Progression by Enhancing Phagocytosis
WO2024036192A2 (en) Compositions and methods for assessing the severity of and treating covid-19
JP2025077049A (ja) Ｃａｒｄ１４を用いた治療、診断およびスクリーニング
US11136368B2 (en) Cancer treatment using CX26 blocking peptides
WO2023088464A1 (zh) Cd300ld抑制剂及其在制备肿瘤免疫治疗产品中的用途
EP1600165A1 (en) Medicinal use of mip-3alpha inhibitor and method of screening brain/nerve cell protective agent
Hartwig Molecular and functional determinants of the TRAIL-induced tumour-supportive secretome
JP2025516174A (ja) Ｔ細胞疲弊を防止するための組成物及び方法
EP1712619A1 (en) Preventive/remedy for cancer
CN116615464A (zh) Itpripl1的调节剂在制备调节免疫反应或抗肿瘤的药物中的用途
CN120131955A (zh) PILRα/CD99通路抑制剂及其应用

Legal Events

Date Code Title Description
FZDE Dead